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Hematopoietic Stem Cell Transplantation with
Antihuman Thymocyte Globulin
Zheng-Ping Yu, Jia-Hua Ding, Fen Wu, Jin Liu, Jun Wang, Jian Cheng, Gang ZhaoThe utility of graft-versus-host disease (GVHD) prophylaxis with cyclosporine (CSA), methotrexate (MTX),
and antihuman thymocyte globulin (ATG) after allogeneic hematopoietic stem cell transplantation
(allo-HSCT) exists in the literature; however, up to now, it has not yet been fully described. This study was
to observe the influence of adding ATG on GVHD prophylaxis and the quality of life (QoL) of 96 hemopathic
patients after allo-HSCT. We retrospectively analyzed the outcomes of 96 consecutive patients undergoing
allo-HSCT, including 54 patients who received ATG regimen without in vitro T cell depletion (TCD) (ATG
group) and 42 patients who received neither ATG regimen nor TCD (control group). All patients were
followed up, and the factors, including age, sex, HLA and ABO compatibility, related and unrelated donors,
and disease status, were undertaken to analysis. All patients in the study achieved trilineage engraftment
with full-donor chimerism. The cumulative incidence of acute GVHD (aGVHD) was lower in the ATG group
than that in the control group (29.6% versus 57.1%, P5.006), and the cumulative incidence of chronic GVHD
(cGVHD) was 35.2% for patients with ATG and 66.7% for patients without ATG (P\ .01). Notably, the
proportion of patients with Karnofsky scores of .90 was 70.4% in the patients with ATG, and 28.6% in
the patients without ATG (P\.001). Furthermore, the cumulative incidence of patients with opportunistic
infection was significantly different in both groups posttransplantation, with 44.4% and 19.1% in recipient
patients with or without ATG respectively (P \ .05). Additional usage of ATG not only decreases the
occurrence of aGVHD and cGVHD, but also improves QoL of patients after allo-HSCTwithout affecting
stem cell engraftment or overall survival.
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Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) has been an increasingly used treatment
in both malignant and nonmalignant hematopoietic
diseases, and it was associated with high rates of
treatment-related morbidity and mortality [1]. Graft-
versus-host disease (GVHD) remains the principal
and most severe complication encountered afterDepartment of Hematology and Hematopoietic Cell
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6/j.bbmt.2011.08.009allo-HSCT [2,3], and the incidents of acute GVHD
(aGVHD) and chronic GVHD (cGVHD) are 30%
to 80% [4-6]. Treatment of related infections is the
main cause of nonrelapse mortality at our institution
and in many others by far [5-7]. Of these, it was most
frequently associated with an overall incidence of
cytomegalovirus (CMV) infection, reaching 50% to
70% [8].
One approach to reducing the incidence of GVHD
and its related mortality is to deplete T cells in vivo by
adding antihuman thymocyte globulin (ATG) to the
pretransplantation conditioning protocol [2,3,9]. As
is well known, health-related quality of life (HRQoL)
of patients has been impaired following HSCT in re-
cent literature, so it is noteworthy that the influence
of additional ATG to the protocol on QoL of patients
with hematopoietic disease deserves further investiga-
tion. Hence, to improve the QoL, we have developed
a prophylaxis regimen that combines cyclosporine/
methotrexate (CSA/MTX) with ATG as an adjuvant
treatment without in vitro T cell depletion (TCD)
for GVHD. In this study, we evaluated the outcome593
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GVHD after allo-HSCT.MATERIALS AND METHODS
Patients
From May 2005 to December 2009, 96 consecu-
tive patients undergoing allo-HSCT in our center
were approved by the institutional review board of
Hematological Institute of Southeast University and
required to sign a written informed consent. There
were 54 patients involved in the ATG with CSA/
MTX prophylaxis (ATG group) and 42 patients who
received CSA/MTX alone (control group). The
median age of the patients was 33 years (range:
14-50 years) in the ATG group and 28 years (range:
12-46 years) in the control group. The characteristics
of the patients including age, sex, HLA and ABO com-
patibility, related and unrelated donors, and disease
status at transplantation was equivalent in 2 groups.
All involved patients had 1 or more of the following
risk factors, including acute leukemia first complete re-
mission with high risk of relapse (more than 2 induc-
tion therapies with residual leukemia cells); induction
therapy needed for more than 5 months; acute leuke-
mia in second complete remission or above; failed to
achieve remission after 2 standard induction therapies.
The time of transplantation was equivalent in all acute
myelogenous leukemia across both groups; chronic
myeloid leukemia in the chronic phase for more thanTable 1. Characteristics of 96 Patients Who Received
Allogeneic Hematopoietic Stem Cell Transplantation
Without ATG With ATG P Value
Number of patients 42 54
Median age (range) 28 (12-46) 33 (14-50) .811





NHL (IVB) 3 2
MDS (RAEB) 4 3
MM 1 1
HLA histocompatibility (n) .316
Related 6/6 identity 17 12
1/6 mismatch 10 19
2/6 mismatch 5 11
Unrelated 6/6 identity 8 10
1/6 mismatch 2 2
ABO compatibility (n) .809
Matched 17 25
Minor mismatch 11 14
Major mismatch 14 15
Donor-recipient relationship (n) .854
Unrelated 10 12
Sibling 32 42
AML indicates acute myeloloid leukemia; ALL, acute lymphocytic leuke-
mia; CML, chromic myeloid leukemia; NHL-IVB, B non-Hodgkin
lymphoma in stage IV; MDS, myelodysplastic syndrome; RAEB, refrac-
tory anemia with excessive blasts; MM, multiple myeloma.2 years; or chronic myeloid leukemia in the accelerated
phase. The demographic characteristics of the recipi-
ents are shown in Table 1.Conditioning Regimen
In this study, 54 patients were involved with adding
ATG to their conditioning regimens, which included
cytarabine (2 g/m2 daily, intravenously [i.v.] for 2
days), cyclophosphamide (1.8 g/m2 daily, for 2 days),
busulfan (0.8 mg/kg administered i.v. in 12 doses for
more than 3 days), simustine (MeCCNU, 250 mg/m2),
and rabbit ATG (4 mg/kg daily i.v. for 4 consecutive
days; Fresenius AG, Oberurse, Germany) (Figure 1).
However, 42 patients received the same conditioning
regimen without additional ATG. The median total
number of hematopoietic mononuclear cells was (3.0-
9.0)  108/kg for patients with additional ATG and
(4.5-7.0)  108/kg for patients without additional
ATG, and that of CD341 cells infused was (3.0-7.0) 
106/kg for patients with additional ATG and (3.0-7.2)
106/kg for patients without additional ATG.Acute GVHD Prophylaxis
All patients received CSA, MTX, and mycopheno-
late mofetil to prevent GVHD. The dose of MTX was
15 mg/m2 i.v. on day11, followed by 10 mg/m2 i.v. on
days13,16, and111 posttransplantation.The dose of
MMFwas 0.5 g every 12 hours orally from day 1 before
transplantation to day 130 posttransplantation. The
dosage of CSA was 3 mg/kg per day intravenously
fromday1before transplantation, andoncebowel func-
tion of the patient was normal, the patient was switched
to the oral route at 5mg/kg/day in 2 divideddoses.Dur-
ing the entire follow-up, CSA concentrations in the
patient’s blood (target plasma level 200-400 ng/mL)
weremonitored biweekly using a fluorescence polariza-
tion immunoassay. From days140 to150, the dose of
CSA was reduced gradually and was stopped on day
1180 if there was no evidence of cGVHD. If cGVHD
developed, CSA was continued [10].Diagnosis and Grading of GVHD
Diagnoses and grades of aGVHD were made in
accordance with modified Seattle Glucksberg criteria
[11], and cGVHD was classified into several cate-
gories, including limited and extensive cGVHD, in
accordance with the extent of the disease [5,12].Figure 1. Cytarabine, busulfan, and cyclophosphamide regimen.
Table 2. Engraftments and Occurrence of GVHD with and




(n 5 54) P Value
Days (range) to neutrophil
engraftment >0.5  109/L




18 (8-45) 20 (9-60) .56
Acute GVHD (%) 24/42 (57.1%) 16/54 (29.6%) .006
Grades I-II 14/42 (33.3%) 12/54 (22.2%)
Grades III-IV 10/42 (23.8%) 4/54 (7.4%) .025
Chronic GVHD 28/42 (66.7%) 19/54 (35.2%) .002
Limited 12/42 (28.6%) 11/54 (20.4%)
Extensive 16/42 (38.1%) 8/54 (14.8%)
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All patients were hospitalized in rooms with high-
efficiency air filters and received standard antibiotic
prophylactic therapy with oral trimethoprim-
sulfamethoxazole. Additionally, patients were admin-
istered ganciclovir between day 29 and day 22 at
a dose of 5 mg/kg per day i.v. before transplantation
[13]. Fluconazole was given i.v. for antifungal prophy-
laxis. Once the patient’s platelet level was below 20 
109/L or the hemoglobin was reduced to 70 g/L during
hospitalization, blood transfusions were given. All
blood products were irradiated before infusion.
Evaluation of Engraftment and Chimerism
Engraftment was defined as absolute neutro-
phils .500/mL for 3 successive days and platelets
.20,000/mL independent of transfusions, which were
monitored by cytogenetic analysis of a bone marrow
aspirate in the first, second, and third month as well
as chimerism studies using short tandem repeat poly-
merase chain reaction and chromosomal fluorescent
in situ hybridization.
Evaluation of QoL
The Karnofsky Performance Scale Index (KPS) is
used to compare the effectiveness of different therapies
in order to assess the prognosis and medical care re-
quirements in individual patients [14,15]. The
European Organization for Research and Treatment
of Cancer Core Quality of Life Questionnaire
(EORTC QLQ-C30, version 1.0) is a well-validated
instrument that assesses HRQoL in cancer patients
[16]. All patients were assessed according to the 5 func-
tional scales (physical, role, emotional, social, and cog-
nitive) and another scale for overall health/global
QoL, and those who scored higher on these scales pos-
sess better function. Meanwhile, 3 symptom scales
measuring fatigue, pain, and nausea and vomiting
and 6 single items assessing symptoms commonly re-
ported by cancer patients (dyspnea, sleep disturbances,
appetite loss, diarrhea, constipation, and financial im-
pact) were also tested, and those who scored higher on
the symptom scales and single items represented
greater symptomatology or impairments. Then mean
scale and item scores were transformed to a 0 to 100
scale as described in the EORTC Scoring Manual
[17]. All patients were evaluated according to the crite-
ria during the 120 days’ follow-up after peripheral
blood stem cell transplantation. Overall survival (OS)
was calculated from the day of transplantation to the
date of the last follow-up visit or death.
Statistical Analysis
Evaluations were based on data available by
December 20, 2009, and final data analysis included
engraftment, incidence of aGVHD and cGVHD,immune reconstitution, and probability of survival.
Patients who survived 6 months or longer were
evaluated for cGVHD. Patients who were alive at final
analysis were censored on the date of the last follow-
up. A log-rank test was applied to compare between
subsets. The Kaplan-Meier method was used to calcu-
late OS and the cumulative incidence for grades III-IV
aGVHD. The QoL was evaluated using EORTC
QLQ-C30 between the 2 groups. All statistical analy-
ses were performed using software package SPSS 11.5
(SPSS, Inc., Chicago, IL) [18], and a P value of\.05
was considered significant.RESULTS
Among all patients undergoing engraftment, full
donor-type chimerism (95%) was seen in 1 month.
The median time to reach a neutrophil engraftment
count of 0.5  109/L was 14 days (range: 10-22 days)
in patients with additional ATG and 13 days (range:
8-20 days) in patients without additional ATG
(P 5 .84), respectively, and the median time to reach
a platelet engraftment count of 20  109/L was
20 days (range: 9-60 days) in patients with additional
ATG and 18 days (range: 8-45 days) in patients with-
out additional ATG (P 5 .56), respectively, and there
was both no statistical difference.
aGVHD and cGVHD
Among the 54 recipient patients with ATG, the
incidence of aGVHD was 29.6% (grade I-II in 16 pa-
tients and grade III-IV in 4 patients); 2 patients died of
severe aGVHD, and 19 patients developed cGVHD
(8 of 19 patients with extensive cGVHD involving
more than 2 organ/systems). In 42 recipient patients
without additional ATG, the incidence of aGVHD
was 80.9% (grade I-II in 24 patients and grade III-IV
in 10 patients); 6 patients died of severe aGVHD and
28 patients developed cGVHD (16 patients with ex-
tensive disease and 12 patients with limited cGVHD).
There were statistically significant differences in
Table 3. HRQoL at ATG or without ATG Groups after He-
matopoietic Stem Cell Transplantation
Without ATG (95% CI) With ATG (95% CI)
(n 5 42) (n 5 54)
Functioning scales*
Cognitive 76 (71-82)† 88 (83-92)
Emotional 72 (68-79) 79 (74-85)
Physical 70 (65-78) 87 (82-93)
Role 61 (53-69) 77 (68-86)
Social 53 (47-61) 62 (54-71)
Global QoL 56 (50-62)‡ 78 (72-83)
Symptom scales§
Fatigue 46 (39-52)‡ 25 (21-30)
Nausea/vomiting 15 (8-20) 11 (7-18)
Pain 22 (15-28) 11 (7-15)
Single items§
Appetite loss 13 (6-20) 8 (2-13)
Constipation 16 (8-23) 4 (0-8)
Diarrhea 18 (9-27) 13 (5-21)
Dyspnea 30 (20-41) 12 (6-18)
Financial impact 12 (5-20) 14 (6-21)
Sleep disturbance 29 (21-37) 14 (7-22)
*Higher scores indicate better functioning.
†Mean (95% confidence interval).
‡P < .01 for differences in mean scores, ATG versus non-ATG groups.
§Higher scores indicate more symptomatology.
Table 4. Clinical Results of Patients Who Received Therapy
with ATG or without ATG Therapy










Infections 12 28.6% 28 51.9% .024
Karnofsky 12 28.6% 38 70.4% .000
score*
Relapse 3 7.14% 9 16.7% .219
Survival 24 57.1% 35 64.8% .289
*Comparison of quality of life according to Karnofsky score >80
(ATG versus non-ATG groups).
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and control group (Table 2).
Opportunistic Infections
There were 28 cases of opportunistic infections in
patients with ATG during the follow-up. Among
them, there were 13 cases in the lung, 2 cases in mouth
cavitymucosa, 9 cases in the bladder, 3 cases in the gas-
trointestinal tract, and 1 case in the central nervous
system. The pathogens found in pneumonia were bac-
teria in 7 cases, Aspergillus in 1 case, Candida albicans in
2 cases, and cytomegalovirus in 3 cases. There were 12
cases of opportunistic infections in patients without
additional ATG; among them, there were 5 cases in
the lung, 2 cases in the skin, 1 case in the bladder, 2
cases in the gastrointestinal tract, and so on. The path-
ogens found in pneumonia were bacteria in 2 cases,
Candida albicans in 1 case, Pseudomonas aeruginosa and
CMV in 1 case. Notably, there were 11 cases of
CMV infection in patients with ATG and only 2 cases
in patients without additional ATG (20.4% versus
4.8%, P 5 .035). The cumulative incidence of oppor-
tunistic infections in the 2 groups was 28.6% versus
51.9% for 4 years’ follow-up after transplantation
(P 5 .024), and there were significant differences be-
tween them (Table 4). Nevertheless, the mortality of
opportunistic infections did not remarkably increase
with or without additional ATG (data not shown).
HRQoL
After allo-HSCT, there were clinically significant
differences at baseline in the direction of betterHRQoL in the ATG group on 9 scales and items.
The differences in global QoL (78 [range: 72-83]) ver-
sus 56 (95% confidence interval [CI]: 50-62) and
fatigue (25 [range: 21-30]) versus 46 (95% CI: 39–52)
were most pronounced. The symptom scores of the
ATG group were similar to the control group at the
1-year assessment, but the social function from 53
(95% CI: 47-61) to 62 (95% CI: 54-71) and role func-
tion from 61 (95% CI: 53-69) to 77 (95% CI: 68-86)
were significantly improved (Table 3). Furthermore,
according to the KPS index, 70.4% of patients with
ATG (38 of 54) were able to live at home and care
for themselves, and 37.0% of patients (25 of 54) were
able to carry on their normal daily activities and return
to work. In the control group, 10 patients required oc-
casional assistance, but were able to care for most of
their personal needs, with a KPS of 60. Sixteen patients
were able to care for themselves, but unable to carry on
normal activities or to do active work, with a KPS of
70. Only 12 patients’ KPSs exceeded 80. In addition,
4 patients without ATG had a KPS of\50. Compared
with 12 patients in the control group and in the ATG
group, 38 patients (70.4%) had scores of at least 80
(13 of 38 patients who developed cGVHD with
a KPS of 90, 25 of 38 patients had a KPS of 100)
(P\ .001), and 4 patients who were able to care for
most of their own personal needs and required
occasional assistance had a KPS of 60. During the
follow-up, KPS was closely monitored and compared
(Table 4), and those who scored .80 corresponded
to an improved prognosis.Relapse and Survival
The ratio of patients who relapsed was similar in
the ATG group and control group (16.7% versus
7.14%, P 5 .219). Up to December 2009, the median
follow-up was 26 months, and 59 of 96 patients sur-
vived. Thirty-five patients with ATG were alive and
the disease OS was 64.8%. The median follow-up
was 605 days (range: 62-1140) in 42 patients without
ATG posttransplantation; among them, the rate of
transplant-related deaths was 9.5% (4 of 42) because
of transplant-related infection, 7.1% (3 of 42) because
Figure 2. Kaplan-Meier curve for OS in patients of both groups after
allo-HSCT. The cumulative OS at 48 months posttransplantation was
64.8% in the ATG group and 57.1% in the control group (P 5 .289).
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GVHD, and 11.9% (5 of 42) because of organ toxicity.
The probability of OS was 64.8% in the ATG group
and 57.1% in the control group (P 5 .289) (Table 4).
The OS of patients in the randomized control trial
was depicted by a Kaplan-Meier curve (Figure 2).DISCUSSION
For many years, allo-HSCT has been limited by
3 major complications including engraftment failure,
severe GVHD, and delayed immune reconstitution
[2,19-21]. An alloresponse by donor T lymphocytes
is probably the cause of GVHD, which is the most
important complication resulting in morbidity and
mortality [2]. GVHD severely affects OS rates as
well as the QoL of patients, especially those using un-
related donors. Some patients failed in conventional
immunosuppressive therapy and succumbed to the de-
pression of their immune systems from GVHD and
secondary infection after all-HSCT [10].
The severity of GVHD and the effects of prolonged
exposure to immunosuppressive therapy influence
transplant-related morbidity. TCD and high-dose
infusions of CD341 cells have been shown to reduce
the incidence of severe GVHD and have improved the
rate of successful engraftment, but the frequency of re-
lapse and infections remains high, and the long-term sur-
vival is poor [22,23]. Yet, thismaybe the reported studies
involved in small numbers of patients without long-term
follow-up [23,24]. Evidence in the literature suggests
that ATG used before HSCT is a standard procedure
to prevent or reduce undesired histoincompatibilityimmune reactions, graft rejection, GVHD, and
nonrelapse mortality [3,25,26]. However, little has
been published about its impact on QoL. We have
summarized the comparative results in a cohort of 96
consecutive patients who underwent peripheral blood
stem cell transplantation in May 2005. This report
depicted the GVHD prophylaxis of the CSA/MTX/
ATG protocol on patients for a 4-year follow-up. We
chose CSA and MTX as a baseline and added ATG
into the preconditioning medium to achieve in vivo
TCD in patients and evaluated the QoL of patients
with hematopoietic diseases. ATG was infused on days
24 to 21 before transplantation to suppress and/or
depletehost lymphocytes aswell as infusedonor lympho-
cytes in vivo to prevent cell-mediated immune responses.
Remberger and his colleagues [27] demonstrate that
ATG could increase the serum level of tumor necrosis
factor alpha in the last 4 days before transplantation
and release anti-inflammatory cytokines, such as
interleukin-10, to down-modulate GVHD. In this con-
text, patients without additional ATG after allo-HSCT
showed a significant severity of GVHD than those with
ATG, suggesting that ATG may improve the recipient
patients’ outcomes.
Because of the immunodeficiency caused by
GVHD and the consequent effects on skin and organic
dysfunction, patients after transplantation are more
vulnerable to infections. Notably, CMV infection
and CMV-related disease are the major complications
after allo-HSCT with a high mortality rate, especially
interstitial pneumonias [28-30]. The cumulative
incidence of opportunistic infections in the 2 groups
was 28.6% versus 51.9% for the 4-year follow-up after
transplantation, and the high infection incidence in the
ATG group is consistent with the use anti-T cell anti-
bodies to decrease cellular immunity for the treatment
of rejection, because active CMV infection is actually
immunosuppressive both in vitro and in vivo, espe-
cially for cell-mediated immune responses [30-32].
Needless to say, the lower morbidity might be
associated with the effective use of ganciclovir
treatment, which is incorporated into viral DNA and
acts as an obligate chain terminator [8,33-36].
Therefore, the use of antiviral therapy for CMV
infection may be a successful strategy to decrease the
incidence and mortality of opportunistic infections.
In long-term survival patients, those who were
given additional ATG seemed to have higher OS com-
pared with those without additional ATG, and the
ratio of patients who relapsed was no striking in the
ATG group compared with that in control group.
Although the patients with additional ATG were asso-
ciated with a reduced risk for aGVHD and cGVHD
and an improved QoL after stem cell transplantation,
the OS did not strikingly improve because of the
increased relapse and transplant-related infections in
the ATG group.
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a useful evaluation standard using the EORTC QLQ-
C30. KPS is used to assess the prognosis and medical
care requirements of our patients. The higher QoL in-
dex supports the report that ATG as part of the prepar-
ative regimen in allo-HSCT reduces the risk of severe
GVHD and infections without affecting the incidence
of relapse [2,37,38]. Although the differences in
relapse rates and OS were not statistically significant,
suggesting that ganciclovir prophylaxis and therapy
decreased CMV infection and/or disease with no
benefit in OS and relapse rates [33], there were longi-
tudinal trends within the intervention group. As we
know, cGVHD has a major negative impact on QoL
of long-term survivors after allo-HSCT [37,39].
However, the combination of CSA/MTX with ATG
seemed to be a very efficient strategy to improve
QoL in our study, which is consistent with previous
reports that the use of ATG had a low incidence of
cGVHD [2,27,37,40]. Even though T lymphocytes,
which are associated with rapid clearance of CMV
infection following allo-HSCT [34,41,42] and may
exert a negative effect on the development of CMV
disease, we believe that therapy with ganciclovir has
contributed to the lower rate of CMV disease in at-
risk patients.
Our results suggest that the administration of
ATG before transplantation is both safe and effective
for GVHD prophylaxis, and there is a similarity in
the efficacy of ATG in decreasing the incidence of
combined MTX/CSA for the prophylaxis of GVHD
in allo-HSCT [43]. More important, better QoL of
patients indicates that the prophylactic regimen with
ATG is feasible and effective on survival without
affecting the engraftment of stem cells. Accounting
for a limited number of patients with various diseases
treated at a single institution and some biases on the
selection of conditioning regimen, a larger multicenter
prospective trial is needed to assess the long-term
benefit of adding ATG into a conditioning regimen.ACKNOWLEDGMENTS
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